Press Releases

Sep 28, 2026, 07:30 ET Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist Phase 1 SAD/MAD study targeted to initiate in the first half of calendar 2027, with initial data targeted in the second

May 18, 2026, 16:00 ET PRINCETON, N.J., May 18, 2026 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will

May 13, 2026, 07:30 ET Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide

Feb 17, 2026, 07:30 ET Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndrome Oral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026 Next-generation

Nov 13, 2025, 07:30 ET Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesity PL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned

Nov 12, 2025, 12:15 ET Trading of Palatin’s common shares resumed trading on NYSE today, November 12, 2025, under the symbol “PTN” PRINCETON, N.J., Nov. 12, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin

Nov 06, 2025, 08:00 ET Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical models Clinical data supports co-administration of an MC4R agonist with tirzepatide as a safe, potentially synergistic approach to weight management PL7737 IND-enabling toxicology underway, with an IND submission and clinical trial initiation planned for the first

Nov 06, 2025, 07:30 ET $15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants Regains compliance with NYSE American exchange listing standard – trading of Palatin’s common shares will resume on November 12, 2025, under the symbol “PTN” PRINCETON, N.J., Nov. 6, 2025 /PRNewswire/

Sep 22, 2025, 07:30 ET Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic macular edema PRINCETON, N.J., Sept. 22, 2025 /PRNewswire/ — Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company advancing medicines that modulate the melanocortin receptor system, today announced the achievement of a research milestone under its

Ingelheim, Germany, and Princeton, New Jersey, USA, August 18, 2025 – Boehringer Ingelheim and Palatin Technologies, Inc., (OTCQB: PTNTD), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced a global research collaboration and licensing agreement aiming to develop an innovative therapy for retinal diseases.